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T2DM is today considered as world-wide health problem, with complications responsible of an enhanced mortality and morbidity.
Thus, new strategies for its prevention and therapy are necessary. For this reason, the research interest has focused its attention
on TLR4 and its polymorphisms, particularly the rs4986790. However, no conclusive findings have been reported until now about
the role of this polymorphism in development of T2DM and its complications, even if a recent meta-analysis showed its T2DM
association in Caucasians. In this study, we sought to evaluate the weight of rs4986790 polymorphism in the risk of the major
T2DMcomplications, including 367 T2DMpatients complicated for the 55.6%. Patients withA/A andA/GTLR4 genotypes showed
significant differences in complication’s prevalence. In particular, AG carriers had higher risk prevalence for neuropathy (𝑃 =
0.026), lower limb arteriopathy (𝑃 = 0.013), and the major cardiovascular pathologies (𝑃 = 0.017). Their cumulative risk was
significant (𝑃 = 0.01), with a threefold risk to develop neuropathy, lower limb arteriopathy, and major cardiovascular events in AG
cases compared to AA cases. The adjusted OR for the confounding variables was 3.788 (95% CI: 1.642–8.741). Thus, the rs4986790
polymorphism may be an indicative of prevalence of complications in T2DM patients.
1. Introduction
Type 2 diabetes mellitus (T2DM) is becoming a common
worldwide disease with epidemic proportions in many pop-
ulations [1]. Environmental changes promoting unhealthy
behaviours and development of obesity and overweight
around the world have been suggested as the principal causes
[2]. In addition, related diabetes complications (i.e. chronic
arterial disease of the lower limbs, carotid arterial diseases,
ischemic heart diseases, neuropathies, nephropathy, chronic
kidney failure) are responsible of an increased morbidity and
mortality [1]. Thus, the knowledge of the pathophysiological
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mechanisms involved in the occurrence of T2DM and related
complications is crucial for successful prevention and new
therapeutic treatments.
It is well-recognised that defective insulin secretion
of pancreatic-𝛽 cells and diminished insulin sensitivity in
peripheral tissues characterise T2DM. In addition, recent
evidence considers the occurrence of T2DM and its compli-
cations as the result of a state of chronic, systemic, and low
grade of inflammation in accordance with metainflamma-
tion hypothesis [3, 4]. Elevated levels of several circulating
inflammatory molecules constitute a common feature in the
natural course of diabetes [5, 6]. Accordingly, pancreatic-
𝛽 cells, under certain pathological condition, produce and
release the proinflammatory cytokine interleukin-1𝛽 (IL-
1𝛽). IL-1𝛽 can in turn impair 𝛽-cell function and induce
apoptosis [7, 8]. In the recent years, it has been also proposed
that T2DM may be the consequence of the stimulation of
Toll-like receptors (TLRs), a family of pattern-recognition
receptors able to detect microbial conserved components
and trigger protective host responses, and implicated in
mediating chronic inflammatory diseases, including obesity
and diabetes [2–4, 9]. Indeed, they also recognize endoge-
nous ligands (i.e., endogenous damage-associated molecular
patterns—DAMPs), such as saturated fatty acids and necrotic
cell products [10, 11]. Interestingly, the activation of TLR4,
one of the best known TLR member, expressed in several
tissue cells, such as cells of the pancreatic islets (i.e., 𝛽-cells
and resident macrophages), can induce both insulin resis-
tance, pancreatic𝛽-cell dysfunction, and alteration of glucose
homeostasis [2, 12–14]. The TLR4 activation seems also to be
exacerbated by the low-grade of circulating endotoxemia (cir-
culating lipopolysaccharide-LPS) correlated with the altered
gut microbiota, which characterizes subjects with metabolic
diseases, such as T2DM [2]. In particular, it has been recently
demonstrated that LPS inhibits 𝛽-cell gene expression of
insulin in a TLR4-manner and via Nuclear Factor (NF)-𝜅B
signaling in pancreatic islets [15]. This crucial role of TLR4
has been confirmed by data demonstrating that deletions or
mutations in TLR4 gene (MIM: 603030) protect against fatty
acid-induced insulin resistance and diet-induced obesity [16–
18]. A lot of single nucleotide polymorphisms (SNPs) were
described in the TLR4 coding region. The +896 A>G SNP
(rs4986790) induces the substitution of Asp299Gly amino
acids, modifying the normal structure of the extracellular
region of theTLR4.Thus, different +896TLR4 genotypesmay
be associated with decreased ligand recognition or protein
interaction anddecreased responsiveness to LPS [9, 19]. Inter-
estingly, a recent meta-analysis showed a significant associ-
ation between +896 TLR4 SNP and T2DM and metabolic
syndrome, in Caucasians [20]. A significant association was
also reported between the Asp299Gly polymorphism of the
TLR4 gene and early onset of diabetic retinopathy. T2DM
patients carryingAG/GGgenotypes showed an increased risk
of developing retinopathy compared with patients carrying
AA genotypes [21].
Overall, although Asp299Gly polymorphism of the TLR4
gene is a well-recognised genetic risk factor in some age-
related diseases [9], only few data have been reported
for T2DM complications, such as neuropathy, retinopathy,
ischemic heart disease, and coronary artery disease [22–27],
and no data were reported on chronic kidney and other
T2DM-related cardiovascular diseases, such as carotid arte-
rial and cerebrovascular diseases and lower limb arteriopathy
in Caucasian populations.
In order to clarify the weight of +896 TLR4A/G polymor-
phism as potential predisposing or protective genetic factor
in themajor T2DMcomplications (neuropathy, nephropathy,
chronic kidney failure, chronic arterial disease of the lower
limbs, carotid arterial diseases, and ischemic heart diseases)
in the Caucasian population, we analysed 367 patients
affected by T2DM and with complications for the 55.6%.
2. Subjects and Methods
2.1. Subject Populations. Three hundred and sixty-seven dia-
betic patients were enrolled. Informed consent was obtained
from each subject. The study protocol was approved by
the Ethics Committee of the INRCA Hospital. T2DM was
diagnosed according to the American Diabetes Association
Criteria [28]. Inclusion criteria were body max index (BMI)
<40 kg/m2, age from 35 to 85 years, ability, and willingness
to give written informed consent and to comply with the
requirements of the study. Information collected included
data on vital signs, anthropometric factors, medical history,
and behaviours as well as physical activity. DNA was col-
lected from participants providing consent to use genetic
material (100 percent of the sample). The presence/absence
of diabetic complications was evidenced as follows: diabetic
retinopathy by fundoscopy through dilated pupils and/or
fluorescence angiography; renal impairment, defined as an
estimated glomerular filtration rate (eGFR) <60mL/min
per 1.73m2 evaluated using Cockcroft-Gault equation [29];
neuropathy established by electromyography; ischemic heart
disease defined by clinical history and/or ischemic electrocar-
diographic alterations; peripheral vascular disease including
atherosclerosis obliterations and cerebrovascular disease on
the basis of history, physical examinations and Doppler
velocimetry technique. Hypertension was defined as a sys-
tolic blood pressure >140mmHg and/or a diastolic blood
pressure >90mmHg, measured while the subjects were sit-
ting, which was confirmed in at least three different occa-
sions. BMI was calculated as weight (kg)/height (m2). All the
selected subjects were Italian and consumed aMediterranean
diet. Overnight fasting venous blood samples of all subjects
were collected from8:00 to 9:00 a.m. in plain, EDTA, heparin,
and citrate added tubes. The samples were either analyzed
immediately or stored at −80∘C for no more than 30 days.
2.2. Laboratory Assays. Blood concentration of fasting glu-
cose, low and high density lipoprotein (LDL and HDL)
cholesterol, and triglycerides was measured using com-
mercially available kits on a Roche/Hitachi 912 (Roche
Diagnostics, Switzerland). Insulin, C-reactive protein (CRP),
apoliprotein-A1, and-B100 (Apo-A1 and Apo-B) levels were
assessed using immunochemical methods and an Access
Analyzer (Beckman Coulter, CA, USA). Creatinine was
measured by Jaffe` method, fibrinogen by Clauss method,
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and urea by a colorimetricmethod. Glycosylated hemoglobin
(HbA1c) levels were measured in all subjects using an HPLC
auto-analyzer Adams HA 8160 (Menarini, Italy). All these
determinations were performed according to the manufac-
turer’s specifications, and quality control was within the
recommended precision for each test.
2.3. Assessment of Insulin Resistance. Insulin resistance was
estimated using the homeostasis model assessment (HOMA-
IR) as described by Matthews et al. [30] and validated by
several authors for epidemiological studies [18]. HOMA-IR
was calculated as the product of fasting glucose (mmol/L) and
fasting insulin (mU/L) divided by 22.5.
2.4. Genotyping. DNA samples of 367 diabetic subjects
were extracted from peripheral blood samples collected in
tripotassium EDTA and purified by using a QIAamp Blood
DNA Maxi kit (Qiagen, Dusseldorf, Germany). Samples
were genotyped for TLR4 Asp299Gly (+896 A/G TLR4;
rs4986790). The procedure for detecting the +896 A/G
TLR4 SNP was based on Restriction Fragment Length
Polymorphism-PCR (RFLP-PCR), restriction cleavage with
NcoI (New England Biolabs, USA), and separation of the
DNA fragments by electrophoresis, as previously described
[31].
2.5. Statistical Analysis. Data were reported as mean (Stan-
dard Deviation) for continuous variables and as percent-
ages (𝑛) for categorical variables. The skewed distributions
(triglycerides, fasting insulin, high-sensitivity C-reactive pro-
tein, fibrinogen, and creatinine) were log-transformed before
statistical analyses to achieve a normal distribution. Differ-
ences between patients without complication and those hav-
ing at least one complication were compared using Student’s
𝑡-test with Bonferroni correction for continuous variables
and 𝜒2 test for categorical variables.
In order to create a dependent binary variable for the
next logistic regression model, we considered neuropathy,
lower limb arteriopathy, and the major cardiovascular events
(MACE) (i.e., carotid arterial diseases, cerebrovascular, and
ischemic heart diseases) complications together (“0” = no
complications; “1” = at least one of the three complications).
Logistic regression models were performed to estimate
the adjusted risk of having at least one of three complications
when AG carrier. Results were expressed as odds ratios (OR)
with 95% CI. Two covariates, urea and LDL cholesterol, were
strongly correlated, respectively, with creatinine and Apo-B
(Pearson’s 𝑟 > 0.5). They were removed as they had less
explanatory power than the other two. Data were analyzed
with SPSS/Win program (version 19.0; Spss Inc., Chicago,
IL). Probability values lower than 0.05 were considered
statistically significant.The reported 𝑃 values were two tailed
in all calculations.
3. Results
3.1. Patient Characteristics. The 367 T2DM diabetics were
characterized to have a mean (Standard Deviation) age of 66
(7.9) years, be males for the 56.7% (precisely 208), and they
were affected by T2DM complications for the 55.6%, includ-
ing neuropathy, nephropathy, chronic kidney failure, chronic
arterial disease of the lower limbs, and MACE (carotid arte-
rial diseases, cerebrovascular and ischemic heart diseases).
In particular, we reported in the Table 1 the comparisons
of anthropometric and biochemical characteristics between
patients without complication and those having at least one
complication (204 versus 163; 55.6% versus 44.4%, resp.).
Thus, we observed that complicated patients were males
for the major number than those without complications. In
addition, they had an older age and showed higher values of
biochemical variables, including fasting glucose, creatinine,
urea, HbA1c, total and LDL cholesterol, and Apo-A1.
3.2. Anthropometric and Biochemical Characteristics of T2DM
Patients Stratified for the A/A and A/G TLR4 Genotypes.
Genotyping the T2DM patients for +896 A/G TLR4 SNP,
we observed that they predominantly had the A/A wild
type genotype (91.5%; 336). The A/G genotype was observed
only in 31 patients (8.5%), while nobody had the G/G
genotype. Stratifying the T2DM patients according to these
genotypes, no statistical significant differences were detected
in their anthropometric and biochemical characteristics, with
exception of total and LDL cholesterol values. Higher values
of total and LDL cholesterol were assessed in patients with
A/A genotype with a 𝑃 = 0.052 and 𝑃 = 0.044, respectively
(Table 2), by evidencing a borderline association.
3.3. The Role of TLR4 Genotypes in T2DM Complications.
With the aim to evaluate the role of +896 A/G TLR4 SNP on
the predisposition of T2DM complications observed in the
population studied, we compared their prevalence in positive
A/A TLR4 individuals versus those positive for A/G TLR4
genotype. A higher significant prevalence was detected for
neuropathy, lower limb arteriopathy, and MACE in positive
A/G TLR4 patients, when compared with those positive for
A/A TLR4 genotype (see Table 3).
In order to analyse the association between complications
and TRL4 polymorphism we considered neuropathy, MACE,
and lower limb arteriopathy complications together (“0” = no
complications; “1” = at least one of these three complications).
The association between complication in the previous three
significant variables and TRL4 polymorphismwas significant
(𝜒2 test = 10.697;𝑃 = 0.01).Thus, we calculated the crude risk
to be complicated in patients with AG genotype obtaining the
following results: OR = 3.403; 95% CI 1.577–7.344.
In addition, we compared the mean values of the main
studied parameters among complicated (at least 1 of 3 com-
plications) and noncomplicated groups, using Student’s 𝑡-test
with Bonferroni correction for continuous variables and 𝜒2
test for categorical variables. We found the following signif-
icant parameters: HbA1c, urea, creatinine, LDL cholesterol,
Apo-A1, and Apo-B (𝑃 < 0.001).
Furthermore, we applied a binary logistic regression
model to estimate the adjusted risk of at least one of three
complications when AG carrier (Table 4). From the model
Azotemia and LDL variables were removed, being redundant
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Table 1: Anthropometric and biochemical characteristics of complicated and no-complicated T2DM patients.
No-complicated cases
(𝑛 = 163)
Complicated cases
(𝑛 = 204) 𝑃
Age (years) 64.03 (8.21) 67.58 (7.36) <0.001
Male(∗) 49.7 (81) 62.3 (127) 0.016
BMI (kg/m2) 28.71 (4.67) 28.71 (4.27) 0.998
Total cholesterol (mg/dL) 202.72 (36.35) 210.86 (37.43) 0.037
HDL-cholesterol (mg/dL) 53.98 (14.78) 51.17 (14.55) 0.069
Triglycerides (mg/dL) 127.97 (91.02) 138.22 (97.91) 0.373
Fasting glucose (mg/dL) 151.74 (36.94) 169.46 (50.84) <0.001
HbA1C (%) 7.08 (10.04) 7.65 (1.25) <0.001
Fasting insulin (uiU/mL) 6.82 (5.06) 6.87 (5.99) 0.691
WBC (103/L) 6.61 (1.54) 6.78 (1.73) 0.307
High-sensitivity C-reactive protein (mg/dL) 4.16 (4.73) 4.20 (6.24) 0.849
Fibrinogen (mg/dL) 301.32 (84.07) 305.96 (74.81) 0.477
Creatinine (mg/dL) 0.85 (0.17) 0.98 (0.37) <0.001
HOMA-IR (mg/dL ∗ uiU/mL) 2.61 (2.42) 2.91 (2.78) 0.267
Urea (mg/dL) 38.56 (9.28) 42.41 (14.20) 0.003
LDL cholesterol (mg/dL) 113.38 (27.06) 120.60 (32.53) 0.024
Apo-A1 (mg/dL) 161.41 (34.67) 170.06 (35.24) 0.020
Apo-B (mg/dL) 99.93 (24.38) 104.94 (27.00) 0.068
Variables are expressed as mean (Standard Deviation).
(∗)Categorical variable expressed as percentage (𝑛).
Table 2: Anthropometric and biochemical characteristics in T2DM patients stratified for the A/A and A/G TLR4 genotypes.
A/A TLR4 positive individuals
(𝑛 = 336)
A/G TLR4 positive individuals
(𝑛 = 31) 𝑃
Age (years) 66.01 (8.01) 65.93 (7.18) 0.958
Male(∗) 55.7 (187) 67.7 (21) 0.195
BMI (kg/m2) 28.59 (4.44) 29.96 (4.38) 0.102
Total cholesterol (mg/dL) 207.48 (37.27) 193.94 (33.70) 0.052
HDL-cholesterol (mg/dL) 52.35 (14.51) 53.13 (16.83) 0.778
Triglycerides (mg/dL) 133.78 (95.54) 132.45 (89.52) 0.822
Fasting glucose (mg/dL) 161.45 (45.95) 163.13 (47.28) 0.846
HbA1C (%) 7.40 (1.18) 7.38 (1.41) 0.940
Fasting insuline (uiU/mL) 6.91 (5.73) 6.17 (3.73) 0.550
WBC (103/L) 6.70 (1.65) 6.77 (1.67) 0.826
High-sensitivity C-reactive protein (mg/dL) 4.20 (5.74) 3.97 (4.04) 0.971
Fibrinogen (mg/dL) 302.02 (78.95) 324.06 (77.87) 0.117
Creatinine (mg/dL) 0.92 (0.31) 0.90 (0.25) 0.726
HOMA-IR (mg/dL ∗ uiU/mL) 2.81 (2.71) 2.47 (1.43) 0.499
Urea (mg/dL) 40.91 (12.67) 38.42 (8.69) 0.284
LDL cholesterol (mg/dL) 117.54 (30.43) 106.05 (28.74) 0.044
Apo-A1 (mg/dL) 165.90 (35.26) 157.81 (34.36) 0.221
Apo-B (mg/dL) 102.54 (25.87) 97.68 (27.05) 0.319
Variables are expressed as mean (Standard Deviation).
(∗)Categorical variable expressed as percentage (𝑛).
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Table 3: Prevalence of complications in T2DMpatients stratified for
A/A TLR4 and A/G genotypes.
A/A TLR4
positive cases
A/G TLR4
positive cases 𝑃
Complicated cases 54.2 (182) 71 (22) 0.071
Neuropathy 18.8 (63) 35.5 (11) 0.026
Nephropathy 12.8 (43) 16.1 (5) 0.599
Kidney failure 3.6 (12) 3.2 (1) 0.921
Retinopathy 30.4 (102) 32.3 (10) 0.826
Lower limb
arteriopathy 5.1 (17) 16.1 (5) 0.013
MACE 17.9 (60) 35.5 (11) 0.017
Variables are expressed as percentage (𝑛).
Table 4: Binary logistic regression model with Odds Ratio (OR)
and 95% confidence intervals of at least one of three complications
(neuropathy, lower limb arteriopathy, and MACE).
Study sample
OR 95% CI 𝑃
TRL4 “A/G” genotype 3.788 1.642–8.741 0.002
Age 1.449 1.027–1.097 <0.001
HbA1c 0.989 1.180–1.780 <0.001
Apo-A1 3.202 0.982–0.996 0.002
Creatinine 0.992 1.248–8.216 0.016
Apo-B 0.983 0.983–1.001 0.067
(Azotemia/creatinine 𝑟 = 0.647; LDL/Apo-B 𝑟 = 0.784).
Thus, we observed the adjusted risk at least one of three
complications when AG carrier (OR = 3.788; 95% CI 1.642–
8.741) (see Table 4).
4. Discussion
T2DM is today considered as world-wide health problem,
as demonstrated by continuous increase of its incidence
essentially linked to obesity and overweight in growing
and constant augment in various populations, such as the
Caucasian populations [1]. In addition, the T2DM individuals
have an enhanced mortality and morbidity due to T2DM-
related complications, including particularly chronic arte-
rial diseases of the lower limbs, carotid arterial diseases,
cerebrovascular, coronary and ischemic heart diseases, neu-
ropathies, nephropathy, and chronic kidney failure [1]. This
implies the necessity to develop new strategies for prevention
and therapy of both T2DM and its complications, even if
the diet and physical activity represent until now the main
basis in their prevention and management. This condition is
leading different researchers to identify appropriate genetic
and molecular factors as potential biomarkers and therapeu-
tic targets, which might permit the early identification of at-
high risk individuals for both T2DM and its complications.
The attention has been particularly focused on inflamma-
tory/immune pathways, including the TLR4 pathway, since
the occurrence of T2DM and its complications is now
considered as the result of a state of chronic, systemic, and low
grade of inflammation in accordance withmetainflammation
hypothesis [2–4]. The focus on TLR4 pathway derives by
different literature data. It has been demonstrated that dietary
macronutrients (i.e., fats and sugars) are able to activate
this pathway [2]. In addition, long-term intake of diets rich
in fats and carbohydrates has been evidenced to provoke
an exacerbated expression and activity of TLR4 in human
monocytes along with increases in superoxide generation,
NF-𝜅B activity, and proinflammatory factors and with a sig-
nificant correlation with HbA1c levels [32–38]. Other studies
performed in animal models showed that over-nutrition or
pathogen infections induce an increased TLR4 expression in
tissues and cell types modulating energy homeostasis and
insulin action, including adipose tissue, pancreatic islets,
muscle, gut, endothelial and smooth muscle cells of arter-
ies, brain, kidney, and liver [2, 34–36]. As result, insulin
resistance, pancreatic 𝛽-cell dysfunction and alteration of
glucose homeostasis, increased production of reactive oxygen
species of polymorphonuclear leukocytes, andmodulation of
natural killer cell functions have been found [2, 12–14, 37–41].
The immune dysfunctions observed seem to clarify the high
susceptibility to infections of lower respiratory and urinary
tracts, skin, andmucousmembranes observed inT2DMcases
[42]. In the complex, these conditions determine and feed as
a vicious cycle a chronic systemic low-grade inflammation,
which seems to be responsible for the onset of metabolic
diseases, such as T2DM and its related complications [43]. In
contrast, it has been demonstrated that insulin reduces LPS-
induced TLR4 expression and activation and oxidative stress
[44, 45]. In addition, recent investigation supports the idea
of involvement of intestinal bacteria in the onset of T2DM
and its complications. Specific intestinal bacteria seem to
operate as LPS sources mediating LPS release and/or bacteria
translocation into the circulation due to vulnerable microbial
barrier and the increased intestinal permeability and to play
a role in systemic inflammation and onset and progression of
T2DM. Pancreatic 𝛽 cells express significant levels of TLR4
which recognize LPS or intestinal bacteria [45, 46].
Based on these recent evidences, TLR4 seems to have the
role of hub in the chronic inflammation observed in T2DM
complications, as currently affirmed by Dasu group [47].
In addition, its activity is modulated by genetic variations,
principally SNPs, such as +896 A>G. This SNP determines
a blunted immune response against viral and bacterial
infections or other exogenous (fats and sugars) endoge-
nous molecules characterized by a reduced production of
proinflammatory cytokines [9, 19]. A recent meta-analysis
evidenced a significant association of AG/GG genotypes
with decreased metabolic disorder risk [20]. In contrast,
few and inconsistent literature data have been reported
on its capacity to be a predisposing or protective genetic
factor for T2DM-related complications, that is, neuropathy,
retinopathy, ischemic heart disease, and coronary artery
disease [22–27]. No literature data exist on TLR4 role in
the T2DM-associated chronic kidney and other T2DM-
related cardiovascular diseases, such as carotid arterial and
cerebrovascular diseases, lower limb arteriopathy, in Cau-
casian populations, although it is well recognised in other
age-related diseases [9]. Thus, the key aim of the present
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study was to analyze the weight of +896 TLR4 A>G SNP
as potential predisposing or protective genetic risk factor
in the major T2DM complications evaluating a population
of 367 patients affected by T2DM and with complications
for the 55.6%, including neuropathy, nephropathy, chronic
kidney failure, chronic arterial disease of the lower limbs,
and MACE. Complicated T2DM patients were characterized
to be prevalently males (62.3%), to have an older age (67.58
versus 64.03 in noncomplicated cases), and to show higher
values of biochemical variables, such as fasting glucose,
creatinine, urea, HbA1c, total and LDL cholesterol, and Apo-
A1 (Table 1). In addition, 91.5% of cases had the of A/A TLR4
genotype and 8.5% had the A/G genotype, while nobody had
the G/G genotype. No associations were observed between
A/A and A/G TLR4 genotypes and their anthropometric
and biochemical characteristics, with exception of total and
LDL cholesterol values (Table 2). In particular, a borderline
association was evidenced (Table 2).
Evaluating the role of +896 A/G TLR4 SNP on the
predisposition of T2DMcomplications, interesting data were,
however, detected. In particular, diabetic carriers of AG
genotype had a major susceptibility for neuropathy, lower
limb arteriopathy, and MACE, as reported in Table 3. Their
cumulative risk was significant (𝑃 = 0.01), with a threefold
risk to develop neuropathy, lower limb arteriopathy, and
major cardiovascular events in AG cases compared to AA
cases (crude OR = 3.403; 95% CI: 1.577–7.344). In addition,
we applied a binary logistic regression model to estimate
the risk, adjusted for confounding variables (HbA1c, urea,
creatinine, LDL cholesterol, Apo-A1, andApo-B), of having at
least one complication of three whenAG carrier.The adjusted
OR was 3.788 (95% CI: 1.642–8.741) as shown in Table 4.
This underlines the remarkable role of this SNP in inducing
T2DM complications independently from other biological
risk factors known to favour the onset of these complications.
5. Limitations
The major limitations of the present study are the relative
small sample size and the necessity to confirm and validate
our data in larger populations of different genetic at least
one of three complications when AG carrier. Despite these
limitations, our study represents the first to have analyzed
the weight of the TLR4 SNPs in of +896 TLR4 A/G poly-
morphism as potential predisposing or protective genetic
risk factor in the major T2DM complications (neuropathy,
nephropathy, chronic kidney failure, chronic arterial disease
of the lower limbs, carotid arterial diseases, and ischemic
heart diseases) in the Caucasian populations. However, fur-
ther studies are required to obtain more conclusive results
and to consider the rs4986790TLR4 SNP a biomarker and the
TLR4 pathway as target for new therapeutic treatment aimed
to prevent or delay the T2DM complications.
6. Conclusions
In the light of the results obtained, a possible explanation
of significant predisposition in the development of diabetic
complications in AG versus AA genotype carriers is likely
due to a compromised immune control against the infectious
diseases. Supporting this hypothesis, we recently demon-
strated that the genetic control of infectious diseases has a
significant role in determining different trajectories to reach
longevity in centenarians [48]. Thus, genetic background
and consequently genetic factors might have a key role in
both onset and progression of T2DM-related complications.
As consequence, our results might open new perspectives
for the analysis of susceptibility factors and prevention for
T2DM-related complications. Actually, these findings might
prompt studies on pharmacological strategies to prevent or
delay the development of T2DM complications in predis-
posed subjects. In addition, they lead to considering the
rs4986790 TLR4 SNP an optimal biomarker to identify at-
risk individuals for T2DM and T2DM-related complications.
Thus, it may be an indicative of prevalence of complications
in T2DM patients.
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